We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Exosome Diagnostics, Takeda Enter Partnership
News

Exosome Diagnostics, Takeda Enter Partnership

Exosome Diagnostics, Takeda Enter Partnership
News

Exosome Diagnostics, Takeda Enter Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Exosome Diagnostics, Takeda Enter Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

As part of the agreement, Exosome Diagnostics will establish a gene expression pipeline with Takeda that will utilize its exosomal RNA isolation technology, RNA-Seq biomarker discovery platform, proprietary algorithms, signal enhancement technology, and additional ancillary technologies for analysis of exosomal RNA. The goal of the pipeline is to develop a platform for serial analysis of gene expression patterns in patients with cancer, as well as additional disease states beyond oncology.

“Analysis of RNAs in exosomes may provide an innovative biomarker tool for longitudinal patient characterization to select patients, monitor disease and track drug response over time of therapy without the need for multiple tissue biopsies. Such monitoring may enable appropriate patient selection to direct the most effective therapy to patients with cancer as well as other indications, such as CNS disorders.” stated Andy Dorner, VP of Translational & Biomarker Research for Takeda. “Specialized omics applications are rapidly changing the landscape of translational medicine; this makes it essential for Takeda to form partnerships with innovative companies, such as Exosome Diagnostics, to further our goal of improving patients’ lives,” Dorner continued. 

“We are excited to begin our partnership with Takeda,” stated Mario Morken, Head of Business Development for Exosome Diagnostics. “Exosome Diagnostics’ technology can enable discovery and development of novel biomarkers that can allow physicians to give the right drug to the right patient at the right time. This partnership highlights Exosome Diagnostics’ capabilities to drive the commercial success of targeted therapies.”

“Exosome is very pleased to be chosen by Takeda for our expertise in exosome isolation and analysis. This collaboration aims to develop a biomarker discovery platform that will further Takeda’s efforts to provide therapeutics that may significantly improve the quality of the patients’ lives,” stated John Boyce, President and CEO of Exosome Diagnostics. “We have made great progress in maturing our biomarker discovery, companion diagnostics development, and commercialization organization over the past year. Takeda is a very well respected and forward-looking company that Exosome Diagnostics is honored to be partnered with,” Boyce continued.

Advertisement